Lumira Ventures

Their thesis, in full

Lumira Ventures is Canada's largest life sciences venture firm, with a thesis-driven approach centered on biotech and medtech with strong clinical impact. The team invests at Series A and B+ in North American companies developing differentiated therapies, medical devices and diagnostic platforms, often located in secondary venture markets outside the coastal hubs. With offices in Toronto, Montreal, Vancouver and Boston, Lumira combines scientific expertise, pharma networks and access to US capital. Its last fully closed vehicle is Fund IV (2021, $295M CAD); Fund V held a first close in April 2026 with a $275M CAD target, extending an 18+ year track record post-MBO from MDS Capital (2007). Cheques of $5M to $25M CAD with a lead posture and long-term support through IPO or strategic acquisition.

Questions they usually ask

Have an answer ready for each one before the first call.

1. Is your therapeutic or device backed by validated clinical or preclinical data with a clear regulatory path?
2. Are you targeting a US or global commercial market large enough for a $5-25M lead cheque?
3. Are you ready to operate with pharma-grade governance and a multi-year capital plan to IND or pivotal trials?

Follow-on

Lumira typically reserves 2-3x the initial cheque for follow-on rounds and leads bridge or extension financings when clinical milestones are hit. Strong syndication muscle into US crossover funds for pre-IPO rounds.

Who to talk to

• Peter van der VeldenExecutive ChairmanLinkedIn ↗
• Gerry BrunkManaging PartnerLinkedIn ↗
• Beni RovinskiManaging DirectorLinkedIn ↗
• Daniel HétuManaging Director
• Jacki JenuthPartner and COOLinkedIn ↗
• Lu HanPartnerLinkedIn ↗
• Nikhil ThattePartnerLinkedIn ↗
• Suman RaoPrincipalLinkedIn ↗